Payment overview · 2025
General Payments
$1,786.87
83 reported records · 19 companies
Healthcare provider profile · identity verified
John M Hill, MD
Allopathic & Osteopathic Physicians|Family Medicine · DELAND, FL · NPI 1558380444
Verified facts
What the public records show
CMS Open Payments records show John M Hill, MD received $1,786.87 in general payments during 2025 across 83 reported records.
Amgen Inc. accounted for 28.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 30 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Mounjaro, Ozempic, Prolia, Rybelsus.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 67 claims for Synthroid by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Prolia by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 125 claims for Farxiga by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 174 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 146 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 176 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $508.87 | 28.5% | 19 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $373.15 | 20.9% | 15 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $176.92 | 9.9% | 10 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $172.26 | 9.6% | 11 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $97.29 | 5.4% | 4 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $94.92 | 5.3% | 6 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $73.87 | 4.1% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $48.13 | 2.7% | 2 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $46.35 | 2.6% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $26.66 | 1.5% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $26.13 | 1.5% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $20.42 | 1.1% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $19.56 | 1.1% | 1 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $19.00 | 1.1% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $18.70 | 1.1% | 1 | 2025 |
| Phadia US Inc. | Unresolved — no canonical attribution shown | $17.10 | 1.0% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $16.28 | 0.9% | 1 | 2025 |
| Stryker Corporation | Unresolved — no canonical attribution shown | $16.26 | 0.9% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $15.00 | 0.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,786.87 | 83 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $415.21 | 13 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $327.81 | 13 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $172.26 | 11 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $155.21 | 11 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $117.35 | 6 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $93.66 | 6 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $73.87 | 4 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $73.87 | 4 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $66.44 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $63.71 | 3 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $59.57 | 4 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $53.23 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $48.13 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $48.13 | 2 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $46.35 | 2 | 2025 |
Source payment records
|
|||||
| Sunosi Normalized: sunosi |
Drug | Axsome Therapeutics, Inc. | $44.06 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $37.18 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $29.47 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $26.66 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $26.13 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $20.42 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $19.56 | 1 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $19.00 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $18.70 | 1 | 2025 |
Source payment records
|
|||||
| ImmunoCAP Normalized: immunocap |
Device | Phadia US Inc. | $17.10 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $16.28 | 1 | 2025 |
Source payment records
|
|||||
| HYDROSET Normalized: hydroset |
Device | Stryker Corporation | $16.26 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $15.00 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $14.50 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $13.56 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 176 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 125 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 174 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 146 | exact normalized | Medicare Part D |
| PROLIA prolia |
2025 | Prolia | 2024 | 20 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 29 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
67 | 29 |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
20 | 13 |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
125 | 30 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
55 | 19 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
174 | 23 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
47 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
146 | 30 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
176 | 52 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
11 | 11 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 641 | 200 |
| Atorvastatin Calcium | Atorvastatin Calcium | 612 | 215 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 437 | 157 |
| Amlodipine Besylate | Amlodipine Besylate | 412 | 139 |
| Losartan Potassium | Losartan Potassium | 389 | 124 |
| Omeprazole | Omeprazole | 377 | 137 |
| Lisinopril | Lisinopril | 360 | 134 |
| Pantoprazole Sodium | Pantoprazole Sodium | 327 | 117 |
| Metoprolol Succinate | Metoprolol Succinate | 274 | 97 |
| Metoprolol Tartrate | Metoprolol Tartrate | 269 | 86 |
| Metformin Hcl | Metformin Hcl | 236 | 81 |
| Gabapentin | Gabapentin | 228 | 74 |
| Alprazolam | Alprazolam | 223 | 59 |
| Furosemide | Furosemide | 218 | 77 |
| Hydrochlorothiazide | Hydrochlorothiazide | 214 | 78 |
| Tamsulosin Hcl | Tamsulosin Hcl | 205 | 77 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 203 | 49 |
| Simvastatin | Simvastatin | 198 | 65 |
| Eliquis | Apixaban | 176 | 52 |
| Mounjaro | Tirzepatide | 174 | 23 |
| Tramadol Hcl | Tramadol Hcl | 172 | 52 |
| Clopidogrel | Clopidogrel Bisulfate | 167 | 59 |
| Duloxetine Hcl | Duloxetine Hcl | 161 | 51 |
| Montelukast Sodium | Montelukast Sodium | 158 | 56 |
| Allopurinol | Allopurinol | 147 | 47 |
| Ozempic | Semaglutide | 146 | 30 |
| Sertraline Hcl | Sertraline Hcl | 132 | 45 |
| Farxiga | Dapagliflozin Propanediol | 125 | 30 |
| Temazepam | Temazepam | 123 | 37 |
| Meloxicam | Meloxicam | 113 | 46 |
| Repatha Sureclick | Evolocumab | 112 | 21 |
| Zolpidem Tartrate | Zolpidem Tartrate | 110 | 47 |
| Finasteride | Finasteride | 104 | 36 |
| Escitalopram Oxalate | Escitalopram Oxalate | 102 | 42 |
| Trazodone Hcl | Trazodone Hcl | 98 | 39 |
| Prednisone | Prednisone | 97 | 51 |
| Potassium Chloride | Potassium Chloride | 95 | 34 |
| Lovastatin | Lovastatin | 93 | 25 |
| Fluticasone Propionate | Fluticasone Propionate | 92 | 41 |
| Fluoxetine Hcl | Fluoxetine Hcl | 90 | 30 |
| Azithromycin | Azithromycin | 86 | 60 |
| Xarelto | Rivaroxaban | 84 | 19 |
| Lorazepam | Lorazepam | 79 | 25 |
| Warfarin Sodium | Warfarin Sodium | 79 | 21 |
| Citalopram Hbr | Citalopram Hydrobromide | 76 | 25 |
| Donepezil Hcl | Donepezil Hcl | 73 | 26 |
| Famotidine | Famotidine | 73 | 27 |
| Atenolol | Atenolol | 72 | 23 |
| Memantine Hcl | Memantine Hcl | 72 | 24 |
| Pravastatin Sodium | Pravastatin Sodium | 72 | 25 |
| Clonazepam | Clonazepam | 71 | 22 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 69 | 19 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 67 | 33 |
| Synthroid | Levothyroxine Sodium | 67 | 29 |
| Buspirone Hcl | Buspirone Hcl | 65 | 24 |
| Ropinirole Hcl | Ropinirole Hcl | 65 | 20 |
| Carvedilol | Carvedilol | 64 | 28 |
| Spironolactone | Spironolactone | 63 | 21 |
| Testosterone Cypionate | Testosterone Cypionate | 57 | 20 |
| Bumetanide | Bumetanide | 55 | 19 |
| Jardiance | Empagliflozin | 55 | 19 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 55 | 12 |
| Tizanidine Hcl | Tizanidine Hcl | 52 | 21 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 52 | 17 |
| Enalapril Maleate | Enalapril Maleate | 51 | 18 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 50 | 20 |
| Bupropion Hcl | Bupropion Hcl | 49 | 16 |
| Estradiol | Estradiol | 49 | 24 |
| Metronidazole | Metronidazole/Sodium Chloride | 49 | suppressed |
| Clindamycin Phosphate-D5w | Clindamycin Phosphate/D5w | 47 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 47 | 16 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 47 | 14 |
| Trulicity | Dulaglutide | 47 | suppressed |
| Valsartan | Valsartan | 47 | 14 |
| Bupropion Xl | Bupropion Hcl | 46 | 14 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 46 | 13 |
| Quetiapine Fumarate | Quetiapine Fumarate | 44 | 15 |
| Ezetimibe | Ezetimibe | 43 | 15 |
| Doxycycline Hyclate | Doxycycline Hyclate | 42 | 34 |
| Ibuprofen | Ibuprofen | 42 | 16 |
| Benazepril Hcl | Benazepril Hcl | 40 | 13 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 39 | 23 |
| Diclofenac Sodium | Diclofenac Sodium | 38 | 17 |
| Propranolol Hcl | Propranolol Hcl | 38 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 37 | suppressed |
| Pregabalin | Pregabalin | 37 | 13 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 35 | 13 |
| Metformin Hcl Er | Metformin Hcl | 35 | 15 |
| Celecoxib | Celecoxib | 34 | 15 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 34 | 26 |
| Alendronate Sodium | Alendronate Sodium | 33 | 14 |
| Diltiazem Hcl | Diltiazem Hcl | 33 | 13 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 33 | 15 |
| Ondansetron Hcl | Ondansetron Hcl | 32 | 22 |
| Pioglitazone Hcl | Pioglitazone Hcl | 32 | suppressed |
| Fenofibrate | Fenofibrate | 31 | suppressed |
| Glipizide | Glipizide | 31 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 31 | 14 |
| Nitroglycerin | Nitroglycerin | 31 | 12 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 30 | 17 |
| Lamotrigine | Lamotrigine | 30 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 30 | suppressed |
| Ramipril | Ramipril | 30 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 29 | 12 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 29 | 14 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 29 | suppressed |
| Folic Acid | Folic Acid | 29 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 29 | 11 |
| Rybelsus | Semaglutide | 29 | suppressed |
| Diazepam | Diazepam | 28 | 14 |
| Mirtazapine | Mirtazapine | 28 | 13 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 28 | 20 |
| Verapamil Er | Verapamil Hcl | 28 | suppressed |
| Fluconazole | Fluconazole | 27 | 19 |
| Myrbetriq | Mirabegron | 27 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 27 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 26 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 26 | suppressed |
| Nystatin | Nystatin | 26 | suppressed |
| Sucralfate | Sucralfate | 26 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 26 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 26 | 15 |
| Vilazodone Hcl | Vilazodone Hcl | 26 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 25 | suppressed |
| Levetiracetam | Levetiracetam | 25 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 25 | 13 |
| Midodrine Hcl | Midodrine Hcl | 25 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 25 | suppressed |
| Insulin Degludec Pen (U-100) | Insulin Degludec | 24 | suppressed |
| Ondansetron Odt | Ondansetron | 24 | suppressed |
| Sotalol | Sotalol Hcl | 24 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 23 | suppressed |
| Cephalexin | Cephalexin | 22 | 20 |
| Liothyronine Sodium | Liothyronine Sodium | 21 | suppressed |
| Amoxicillin | Amoxicillin | 20 | 12 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 20 | 16 |
| Brilinta | Ticagrelor | 20 | suppressed |
| Chlorthalidone | Chlorthalidone | 20 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 20 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 20 | 12 |
| Lansoprazole | Lansoprazole | 20 | suppressed |
| Nitroglycerin Patch | Nitroglycerin | 20 | suppressed |
| Prolia | Denosumab | 20 | 13 |
| Amiodarone Hcl | Amiodarone Hcl | 19 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 19 | suppressed |
| Digoxin | Digoxin | 19 | suppressed |
| Entresto | Sacubitril/Valsartan | 19 | suppressed |
| Metronidazole | Metronidazole | 19 | 16 |
| Nifedipine Er | Nifedipine | 19 | suppressed |
| Primidone | Primidone | 19 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 18 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 17 | suppressed |
| Estradiol (Twice Weekly) | Estradiol | 17 | suppressed |
| Methylprednisolone | Methylprednisolone | 17 | 15 |
| Praluent Pen | Alirocumab | 17 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 17 | 11 |
| Acyclovir | Acyclovir | 16 | suppressed |
| Adacel Tdap | Diph,pertuss(Acell),tet Vac/Pf | 16 | 16 |
| Anastrozole | Anastrozole | 16 | suppressed |
| Eszopiclone | Eszopiclone | 16 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 16 | suppressed |
| Baclofen | Baclofen | 15 | suppressed |
| Carisoprodol | Carisoprodol | 15 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 15 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 15 | suppressed |
| Levofloxacin | Levofloxacin | 15 | 13 |
| Methocarbamol | Methocarbamol | 15 | suppressed |
| Mupirocin | Mupirocin | 15 | 14 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 15 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 15 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 14 | suppressed |
| Gammagard Liquid | Immun Glob G(Igg)/Gly/Iga Ov50 | 14 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 14 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 14 | suppressed |
| Ketoconazole | Ketoconazole | 14 | suppressed |
| Levemir Flexpen | Insulin Detemir | 14 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 14 | suppressed |
| Linzess | Linaclotide | 14 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 14 | suppressed |
| Naproxen | Naproxen | 14 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 14 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 14 | 12 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 13 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 13 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 13 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 13 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 13 | suppressed |
| Risperidone | Risperidone | 13 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 12 | suppressed |
| Lidocaine | Lidocaine | 12 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 12 | suppressed |
| Repatha Syringe | Evolocumab | 12 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 12 | suppressed |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 11 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 11 | suppressed |
| Januvia | Sitagliptin Phosphate | 11 | suppressed |
| Novolog Flexpen | Insulin Aspart | 11 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 11 | 11 |
| Prazosin Hcl | Prazosin Hcl | 11 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 11 | suppressed |
| Ranolazine Er | Ranolazine | 11 | suppressed |
| Saxagliptin Hcl | Saxagliptin Hcl | 11 | suppressed |
| Ulticare Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,786.87 · 83 records | Amgen Inc. | ACCRUFER, AIRSUPRA, Auvelity, BREZTRI, ELIQUIS, EVENITY, FARXIGA, FREESTYLE LIBRE 3, GEMTESA, HYDROSET, INSPIRE, ImmunoCAP, Kerendia, Korlym, LEQVIO, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, PROLIA, QULIPTA, REPATHA, Rybelsus, Sunosi, The Cologuard Plus Collection Kit, UBRELVY, VRAYLAR, Veozah, XIFAXAN, ZEPBOUND | 14 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error